Exicure
Open
$2.80
Prev. Close
$2.80
High
$2.80
Low
$2.78
Market Snapshot
$17.72M
-1.8
-4.79
$500K
8
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Recently from Cashu
Exicure Expands Cancer Treatment Potential with Acquisition of GPCR Therapeutics
Exicure Expands Therapeutic Horizons with Strategic Acquisition of GPCR Therapeutics Exicure, Inc. announces a pivotal acquisition that positions the company for significant advancements in cancer tre…
Exicure Acquires GPCR Therapeutics to Enhance Cancer Treatment Innovations
Exicure Expands Its Therapeutic Portfolio with Strategic Acquisition of GPCR Therapeutics Exicure, Inc. has recently solidified its commitment to advancing innovative cancer therapies through the acqu…
Exicure Acquires GPCR Therapeutics to Enhance Research in Biotech Drug Development
Exicure Expands Its Research Horizons with GPCR Therapeutics Acquisition Exicure, Inc. has signed a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc., marking a significant step in the co…
Exicure Strengthens Biotech Position with Acquisition of GPCR USA for Enhanced Drug Development
Exicure Expands Drug Development Capabilities Through Acquisition of GPCR USA Exicure, Inc. has solidified its position in the biotech landscape by signing a Memorandum of Understanding (MOU) with GPC…